If you have schizophrenia, your doctor may want you to take aripiprazole. That’s a prescription drug sold under the brand name Abilify. Aripiprazole is an atypical or second-generation antipsychotic ...

Aripiprazole is a generic prescription drug that’s used to treat certain neurological and mental health conditions. Its cost may depend on factors such as your dosage, whether you have health ...

Aripiprazole is a generic prescription medication that’s prescribed for certain mental health conditions. Aripiprazole belongs to a class of drugs a called atypical antipsychotics. A class of drugs is ...

Abstract and Introduction Clinical Profile of Aripiprazole as Reflected by Clinical Trial Data Use of Aripiprazole in the Treatment of Schizophrenia: Consensus Report Conclusion References Control of ...

Aripiprazole is a generic prescription drug used to treat certain mental health conditions. It’s also available as the brand-name drug Abilify. Aripiprazole can cause side effects that range from mild ...

Review the side-effects of Aripiprazole as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of ...

Aripiprazole is a generic drug prescribed for certain conditions, including schizophrenia, in adults and some children. The medication is available as the brand-name drugs Abilify, Abilify Asimtufii, ...

While aripiprazole has long been a standard treatment for psychiatric disorders, such as schizophrenia and bipolar disorder, recent studies indicate that it is effective in treating circadian rhythm ...

Alkermes announced results from its Phase 3 trial of aripiprazole lauroxil, an investigational drug for the treatment of schizophrenia. Aripiprazole lauroxil is an injectable atypical antipsychotic ...

Aripiprazole was recently US FDA-approved to treat irritability in children and adolescents with autistic disorder aged 6–17 years. There are currently only two psychotropics approved by the FDA to ...

Aripiprazole (Abilify, Bristol-Myers Squibb and Otsuka Pharmaceuticals) has a UK marketing authorisation for the treatment of schizophrenia in people aged 15 years and older. The initial marketing ...